The ACR responded to a Senate Health Committee request for information with legislative strategies to support healthcare providers and expand the physician and care team pipeline.
Litifilimab Promising for Cutaneous Lupus Erythematosus
A study found that litifilimab, a humanized monoclonal antibody that binds blood dendritic cell antigen 2, may be effective for the treatment of patients with active cutaneous lupus erythematosus. The treatment successfully reduced skin disease activity in patients at 16 weeks compared with placebo.
Drug Enforcement Agency Outlines New Training Requirements
Starting in June, all prescribers registered with the Drug Enforcement Agency must complete a one-time, eight-hour training on treating and managing patients with opioid or substance use disorders.
Updated Information about End of Public Health Emergency May 11
The ACR is compiling a list of healthcare policy changes relevant to rheumatology providers and patients that will take effect when the public health emergency expires on May 11.
Anti-P. copri Antibody Responses in Patients with RA
Background & Objectives Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with immune responses to the patient’s own antigens and characterized by inflammation and substantial joint destruction. Prevotella copri, a gut commensal bacterium, has been reported to be an immune-relevant organism in individuals with RA. This study sought to evaluate antibody responses to anti-P….
Diet May Help Reduce Inflammation in RA
In a small study, an anti-inflammatory diet helped reduce pain and swelling in a subset of people with rheumatoid arthritis (RA). Diet changes are complementary to standard treatment. Diet-related research can be challenging, but many patients with RA are motivated to try healthy changes.
The ACR Recommends Inflation-Based Medicare Payment Updates
In a letter to Congress, the ACR, AMA and other groups urge legislation that would provide annual inflation-based Medicare payment updates based on the full Medicare Economic Index.
COVID-19 EUA Testing Requirement Change
On Feb. 3, the U.S. Food & Drug Administration (FDA) revised its Letters of Authorization for two emergency use authorizations (EUAs), Paxlovid and Lagevrio, to remove the requirement for positive test results to prescribe these drugs. The agency continues to recommend that providers use direct SARS-CoV-2 viral testing to help diagnose COVID-19. The FDA recognizes…
What We Know about COVID-19 in 2023: Variants, Vaccines, New Therapies & More
Although a less central focus than it was three years ago, rheumatologists must still consider the prevention and management of SARS-CoV-2 in their patients. The following update shares ongoing considerations related to the COVID-19 pandemic. Outcomes At the beginning of the pandemic, it was unclear whether patients with rheumatic disease would be at higher risk…
Long COVID: Experts Weigh in on Increasingly Common Syndrome
A minority of patients experience lingering symptoms after infection with SARS-CoV-2, similar to some other previously known post-infection syndromes. Although we are just beginning to understand the different presentations, pathophysiology, risk factors, prognosis and treatment of long COVID, rheumatologists can play a leadership role in managing patients with the illness and contributing to this important research…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 330
- Next Page »